PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin

Overview

Journal J Pediatr Surg

Specialties General Surgery
Pediatrics

Date 2024 Apr 3

PMID 38570263

Authors

Janet R Julson

Colin H Quinn

Nazia Nazam

Laura V Bownes

Jerry E Stewart

Elizabeth A Beierle

Affiliations

Soon will be listed here.

Abstract

Background: Chemoresistance contributes to relapse in high-risk neuroblastoma. Cancer cells acquire resistance through multiple mechanisms, including drug efflux pumps. In neuroblastoma, multidrug resistance-associated protein-1 (MRP1/ABCC1) efflux pump expression correlates with worse outcomes. These pumps are regulated by PIM kinases, a family of serine-threonine kinases, overexpressed in neuroblastoma. We hypothesized PIM kinase inhibition would sensitize neuroblastoma cells by modulating MRP1.

Methods: Kocak database query evaluated ABCC1, PIM1, PIM2, and PIM3 expression in neuroblastoma patients. SK-N-AS and SK-N-BE(2) cells were treated with doxorubicin or the pan-PIM kinase inhibitor, AZD1208. Flow cytometry assessed intracellular doxorubicin accumulation. AlamarBlue assay measured viability. The lethal dose 50% (LD) of each drug and combination indices (CI) were calculated and isobolograms constructed to determine synergy.

Results: Kocak database query demonstrated positive correlation between PIM genes and ABCC1. PIM kinase inhibition increased intracellular doxorubicin accumulation in both cell lines, suggesting PIM kinase regulation of MRP1. Isobolograms showed synergy between AZD1208 and doxorubicin.

Conclusions: The correlation between PIM and ABCC1 gene expression suggests PIM kinases may contribute to neuroblastoma chemotherapeutic resistance. PIM kinase inhibition increased intracellular doxorubicin accumulation. Combination treatment with AZD1208 and doxorubicin decreased neuroblastoma cell viability in a synergistic fashion. These findings support further investigations of PIM kinase inhibition in neuroblastoma.

Type Of Study: Basic Science Research.

Level Of Evidence: NA.

References

Haber M, Bordow S, Gilbert J, Madafiglio J, Kavallaris M, Marshall G . Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene. 1999; 18(17):2777-82. DOI: 10.1038/sj.onc.1202859. View

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

Henderson M, Haber M, Porro A, Munoz M, Iraci N, Xue C . ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst. 2011; 103(16):1236-51. PMC: 3156802. DOI: 10.1093/jnci/djr256. View

Nawijn M, Alendar A, Berns A . For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2010; 11(1):23-34. DOI: 10.1038/nrc2986. View

Kauffman M, Kauffman M, Zhu H, Jia Z, Robert Li Y . Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. React Oxyg Species (Apex). 2018; 2(6):432-439. PMC: 5921830. DOI: 10.20455/ros.2016.873. View

Choi Y, Yu A . ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des. 2013; 20(5):793-807. PMC: 6341993. DOI: 10.2174/138161282005140214165212. View

Chou T . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947. View

Iida S, Sunami K, Minami H, Hatake K, Sekiguchi R, Natsume K . A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma. Int J Hematol. 2021; 113(6):797-806. DOI: 10.1007/s12185-021-03096-9. View

Mancilla T, Iskra B, Aune G . Doxorubicin-Induced Cardiomyopathy in Children. Compr Physiol. 2019; 9(3):905-931. PMC: 7000168. DOI: 10.1002/cphy.c180017. View

10.

Julson J, Quinn C, Bownes L, Hutchins S, Stewart J, Aye J . Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype. J Pediatr Surg. 2023; 58(6):1155-1163. PMC: 10198809. DOI: 10.1016/j.jpedsurg.2023.02.018. View

11.

Rozen S, Skaletsky H . Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 1999; 132:365-86. DOI: 10.1385/1-59259-192-2:365. View

12.

Winer J, Jung C, Shackel I, Williams P . Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999; 270(1):41-9. DOI: 10.1006/abio.1999.4085. View

13.

Xie Y, Xu K, Linn D, Yang X, Guo Z, Shimelis H . The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2007; 283(6):3349-3356. DOI: 10.1074/jbc.M707773200. View

14.

Peterson B, Tan K, Osa-Andrews B, Iram S . High-content screening of clinically tested anticancer drugs identifies novel inhibitors of human MRP1 (ABCC1). Pharmacol Res. 2017; 119:313-326. DOI: 10.1016/j.phrs.2017.02.024. View

15.

Vander Borght S, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S . Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 2008; 28(10):1370-80. DOI: 10.1111/j.1478-3231.2008.01889.x. View

16.

Al-Malky H, Al Harthi S, Osman A . Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2019; 26(2):434-444. DOI: 10.1177/1078155219877931. View

17.

Leslie E, Deeley R, Cole S . Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005; 204(3):216-37. DOI: 10.1016/j.taap.2004.10.012. View

18.

Xie Y, Burcu M, Linn D, Qiu Y, Baer M . Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol. 2010; 78(2):310-8. PMC: 11037423. DOI: 10.1124/mol.109.061713. View

19.

Pritchard-Jones K, Pieters R, Reaman G, Hjorth L, Downie P, Calaminus G . Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol. 2013; 14(3):e95-e103. DOI: 10.1016/S1470-2045(13)70010-X. View

20.

Darby R, Unsworth A, Knapp S, Kerr I, Callaghan R . Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors. Cancer Chemother Pharmacol. 2015; 76(4):853-64. DOI: 10.1007/s00280-015-2858-9. View